Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.
Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, Nakatani T, Kikuchi E, Moriyasu H, Matsumoto M, Sato S, An T, Morita H, Aizawa S, Tokuoka Y, Ishikawa M, Matsumura Y, Ohira H, Kogure A, Noguchi K, Yoshiji H.
Mashitani T, et al. Among authors: kikuchi e.
Biomed Rep. 2016 Feb;4(2):183-187. doi: 10.3892/br.2016.569. Epub 2016 Jan 7.
Biomed Rep. 2016.
PMID: 26893835
Free PMC article.